ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

Hvivo Takeover Rumours (HVO)

Hvivo Chart

Hvivo Takeover Price

Hvivo Takeover Forum Posts

14-03-2024
Stt, you make so many stupid statements it's actually laughable. At least you tacitly agree that HVO should be worth 4x revenue so I presume you'll think a fair valuation is 4x the results in April. The thing you stupidly forgot though, was the small matter of 37m in cash. So precited revenue of 62m (we all know it will be higher) x 4, plus the latest cash position is £285m or an SP of over 42p and that's without calculating in any increase in revenue or cash positions PLUS ignoring the fact ergomed was considered a cheap takeover PLUS the fact that revenue is forecast to hit £100m over the following years, so why sell now. Exciting times for one of the most highlighted companies of 2024 for takeover potential
JPM London taking their holding to over 5% is a positive endorsement on future growth and possible sale or takeover acquisition by a big Pharma who could effectively “controlâ€￾ the Human Challenge Study market?
03-02-2024
Https://www.genengnews.com/a-lists/top-10-biopharma-takeover-targets-of-2024/ Includes Hvivo Even more interesting, perhaps, is that it is the only UK listed company included!
02-02-2024
hxxps://www.genengnews.com/a-lists/top-10-biopharma-takeover-targets-of-2024/ Includes Hvivo
30-01-2024
Another healthcare company called APH (LSE) , mcap 200m but revenue 183m , cash in bank 21m , profit 43m , takeover offer was 400m last year but company rejected that offer . i will invest their because of good value. here i will wait until mcap go down
10-01-2024
1gw, What is the bull case here? What do you think of the declining cash, the lack of strong revenue growth? The bear points: This is being talked up before the TU. The CEO's huge 7m options are exercisable in a year. What is the bull case? My bear points are: No evidence of institutionS being major holders > 3% No evidence of significant buying by institutions in 2023, 2022, 2021... CEO has huge options, which are due to exercise in a year. Only 1 director granted them. Declining cash, despite warrant holders selling and income now being received from Polb. Lack of strong revenue growth expectation, despite the new facility. Huge shares on loan The previous company Nomad(replaced this week) had a target price of 29p, based on Peer's takeover. IF HVO receive a bid. Missed expectations. Mcap £170m with £55m revenues.
09-01-2024
This is being talked up before the TU. The CEO's huge 7m options are exercisable in a year. What is the bull case? My bear points are: No evidence of institutionS being major holders > 3% No evidence of significant buying by institutions in 2023, 2022, 2021... CEO has huge options, which are due to exercise in a year. Only 1 director granted them. Declining cash, despite warrant holders selling and income now being received from Polb. Lack of strong revenue growth expectation, despite the new facility. Huge shares on loan The previous company Nomad(replaced this week) had a target price of 29p, based on Peer's takeover. IF HVO receive a bid. Missed expectations. Mcap £170m with £55m revenues. Have a look at Trmr thread. It's quiet when this thread was busy and vice versa.
05-01-2024
1gw, Instead of trader talk, how about you counter the reasonable bear points I've raised. How about some analysis? Obviously you won't because you know they are real concerns. No evidence of institutions being major holders > 3% No evidence of significant buying by institutions in 2023, 2022, 2021... Mo, CEO has huge options, which are due to exercise in a year. CF (founder, ex CEO) is a major holder where his buy is now around break even. Declining cash, despite warrant holders selling and income now being received from Polb. Lack of strong revenue growth expectation, despite the new facility. Huge shares on loan Company Nomad has a target price of 29p, based on Peer's takeover. IF HVO receive a takeover. Mcap £170m with £55m revenues, declining cash. Missed expectations/questionable business model.
02-01-2024
elrico, "Where are your bear points? " My bear points: No evidence of institutions being major holders > 3% No evidence of significant buying by institutions in 2023, 2022, 2021... Mo, CEO has huge options, which are due to exercise in a year. CF (founder, ex CEO) is a major holder where his holding is now around break even. Declining cash, despite warrant holders selling and income now being received from Polb. Lack of strong revenue growth expectation, despite the new facility. Huge shares on loan Company Nomad has a target price of 29p, based on Peer's takeover. IF HVO receive a takeover. Mcap £170m with £55m revenues, declining cash. Missed expectations/questionable business model.
Chica, 4x£55m (fy2023 revenue) is £220m. Which isn't far off the company Nomad's target of 29p. IF there is a takeover bid around that price then the Nomad, who's remit is to advice the company, would suggest it's a fair offer. Declining cash, lack of revenue growth, MO has huge 7m options, huge shares on loan, questionable business model. Trading not holding has been the best option.
18-12-2023
Good to see Simon Thompson (Investors Chronicle) including HVO in his list of “5 Small Caps Targeted for possible Takeover in 2024â€￾
16-12-2023
Great to see Simon Thompson (IC) including HVO in his “5 small-cap takeover targets to exploitâ€￾ article this weekend. This will give strong buying momentum on Monday opening together with shorters having to close their positions as their losses accumulate (Sikh in particular!)
15-12-2023
Strong momentum and 12 month all time high on breakout today. Shares that end the week on a high tend to continue that trend on Monday. Confident HVO will be over 40p in 2024 sometime or will be targeted for takeover given the global monopoly hold and expertise it has in conducting Human Challenge Studies.
12-12-2023
"Bearing this in mind, private equity group Permira recently acquired rival Ergomed on a current-year PE ratio of 29.6 and on 15.1 times cash profit to enterprise valuation – a massive 62 per cent premium to hVIVO’s current rating. Either the shares will re-rate, or hVIVO could expect a knock on the door from a private equity buyer." "The shares... could easily command a valuation 75 per cent higher still if hVIVO is bid for. Buy." Https://www.investorschronicle.co.uk/ideas/2023/12/08/four-small-cap-takeover-targets-to-exploit/
11-12-2023
How do we know a takeover is how this will end 🤷â€￾♂ï¸￾
Four small-cap takeover targets to exploit suggest @IChronicle“Aim-traded #HVO is a fast-growing specialist contract research organisation in a strong earnings upgrade cycle. @hVIVO_UK is cash-rich and lowly rated, making it easy prey”https://www.investorschronicle.co.uk/ideas/2023/12/08/four-small-cap-takeover-targets-to-exploit/
18-10-2023
Richardson may be a poison pill for anything except a cash takeover.
16-10-2023
Manc10, "Small.for jp.morgan chase could be billions they would class that as small a huge company assets of 2.6 trillion usd" Agree, it could be small compared to their fund size. However, there's no holding rns so, from HVO, or any company holding point of view, it's not a major holding. It's not unusual for brokers to trade or take a punt. sci102 has previously said JPM hold 20m. Yet he thinks 10-11m (1.5%) Shares on Loan is nothing!!! Red flags: Questionable business model. Huge options for 1 executive Huge Shares on Loan No evidence of significant buying by IIs/funds. Companies own broker has tp in mid 20s, which is based on comparison to Ergomed's takeover price.